New insulin candidate GZR33 faces off against degludec in early trial
NCT ID NCT07242664
First seen Nov 21, 2025 · Last updated May 24, 2026 · Updated 21 times
Summary
This early-phase study is testing a new long-acting insulin called GZR33 in 12 adults with type 1 diabetes. The goal is to see how well it controls blood sugar compared to an existing insulin (degludec), and to check its safety and how the body processes it. Participants must be 18-64, have had type 1 diabetes for at least a year, and be on a stable insulin routine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil
RECRUITINGNeuss, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Profil Institut
RECRUITINGNeuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.